BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15853638)

  • 1. Obesity and cardiovascular physiology: impact of some pharmacological agents.
    Chaput JP; Bérubé-Parent S; Tremblay A
    Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacotherapy in the treatment of obesity].
    Hamann A
    MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
    Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A
    Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacotherapy of obesity].
    Tripp B; Ludvik B
    Wien Med Wochenschr; 2004 Jul; 154(13-14):320-8. PubMed ID: 15368953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and novel approaches to the drug therapy of obesity.
    Chaput JP; Tremblay A
    Eur J Clin Pharmacol; 2006 Oct; 62(10):793-803. PubMed ID: 16937118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
    Rubio MA; Gargallo M; Isabel Millán A; Moreno B
    Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
    Coutinho W
    Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):262-70. PubMed ID: 19466219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in obesity pharmacotherapy.
    Mayer MA; Höcht C; Puyó A; Taira CA
    Curr Clin Pharmacol; 2009 Jan; 4(1):53-61. PubMed ID: 19149502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity, cardiovascular risk and pharmacotherapy.
    Ruilope LM; Garcia-Robles R; Moreno B
    Blood Press; 2002; 11(5):260-2. PubMed ID: 12458647
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anti-obesity drugs: sibutramine and orlistat].
    Sempere I Verdú E; Palop Larrea V; Hidalgo Mora JJ; Martínez-Mir I
    Med Clin (Barc); 2002 Mar; 118(11):437; author reply 437-8. PubMed ID: 11943108
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
    Caterson ID; Finer N
    Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.